Construction of CF 2 moieties in FDA-approved drugs (2016–2025): industrial routes, mechanisms, and scale-up considerations
Beilstein Journal of Organic Chemistry · 04.08.2026 · 22 · 1122-1150
DOI: 10.3762/bjoc.22.91 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Beilstein Journal of Organic Chemistry, online erschienen am 04.08.2026. Verfasst von Wenyan Yao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shaanxi Institute of International Trade & Commerce, Xianyang, 712046, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The incorporation of CF 2 moieties into drug molecules offers unique advantages in improving metabolic stability and target affinity, making their efficient construction a major focus in pharmaceutical process chemistry. This review systematically examines the synthetic processes of 12 FDA-approved CF 2 -containing drugs from 2016 to 2025, categorizing them according to the chemical environment of the CF 2 group (alkyl-CF 2 , heteroaryl-CF 2 , and ArO-CF 2 ). For each drug, the industrial routes for CF 2 construction and the reasons for eliminating alternative routes are analyzed. Methods for CF 2 formation are classified into two major strategies: fluorinating reagent-based approaches and building block-based approaches. Key process steps and scale-up data are summarized in Table 1. The article systematically discusses four types of reaction mechanisms – nucleophilic fluorination, electrophilic fluorination, radical pathways, and carbene insertion – and evaluates their applicability in industrial production. The analysis shows that for alkyl-CF 2 groups, the industry strongly favors preformed CF 2 building blocks or indirect fluorination strategies to avoid hazardous reagents and harsh conditions. Continuous flow technology using SF 4 has emerged as an important complement to traditional fluorination methods. For heteroaryl-CF 2 groups, metal-catalyzed direct introduction of the CF 2 unit still faces challenges for industrial application, whereas the difluorocarbene route for ArO-CF 2 has been validated. This review provides a reference for process development of new CF 2 -containing drugs, from strategic design to scale-up evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shaanxi Institute of International Trade & Commerce, Xianyang, 712046, China.
- Shaanxi Buchang Pharmaceutical Co., Ltd., Xi'an, 710075, China.
Zitieren
APA
Yao, W., Zhang, H., Yang, X., & Liu, F. (2026). Construction of CF 2 moieties in FDA-approved drugs (2016–2025): industrial routes, mechanisms, and scale-up considerations. Beilstein Journal of Organic Chemistry, 22, 1122-1150. https://doi.org/10.3762/bjoc.22.91
Vancouver
Yao W, Zhang H, Yang X, Liu F. Construction of CF 2 moieties in FDA-approved drugs (2016–2025): industrial routes, mechanisms, and scale-up considerations. Beilstein Journal of Organic Chemistry. 2026;22:1122-1150. doi:10.3762/bjoc.22.91
BibTeX
@article{Yao2026,
author = {Yao, Wenyan and Zhang, Huanhuan and Yang, Xiaolong and Liu, Feng},
title = {Construction of CF 2 moieties in FDA-approved drugs (2016–2025): industrial routes, mechanisms, and scale-up considerations},
journal = {Beilstein Journal of Organic Chemistry},
year = {2026},
volume = {22},
pages = {1122--1150},
doi = {10.3762/bjoc.22.91}
}
EUVIMED